Biodefense Grants and Contracts
FY2007 Awards
In fiscal year (FY) 2007, NIAID awarded a number of grants and contracts to expand scientific research and development for biodefense. These initiatives have been categorized according to the following four areas:
- Basic Research—programs to investigate pathogen biology, host response, microbial genomic sequencing, and proteomics
- Product Development—initiatives to support all phases of development of a candidate product or platform technology, including development of vaccines, therapeutics, and diagnostics
- Clinical Research—initiatives to evaluate biodefense therapies, vaccines, and diagnostics
- Research Resources—initiatives to build biodefense research capacity and infrastructure
Details concerning specific initiatives and related award information may be found below.
Biodefense and Emerging Infectious Diseases Research Opportunities
Objective: To support basic and applied research on NIAID Category A, B, and C Priority Pathogens, their toxic products, and the body's immune defenses against them.
Contact Info
Samuel Perdue
E-mail: sperdue@niaid.nih.gov
Non-Antibiotic Selectable Markers for Biodefense
Objective: To support research that will lead to development of non-antibiotic selectable genetic markers for NIAID Category A, B, or C bacterial agents.
Contact Info
Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Training and Career Development for Biodefense and Emerging Diseases
Objective: To ensure that an adequate cadre of well-trained and motivated investigators are available to pursue research and development objectives in biodefense and emerging diseases.
Contact Info
Susan Garges
E-mail: sgarges@niaid.nih.gov
Cooperative Research Partnerships for Influenza Product Development (U01)
Objective: To support research that will advance the development of vaccines, adjuvants, therapeutics, immunotherapeutics, and diagnostics for influenza technologies through the product development pathway.
Contact Info
General scientific, technical, and programmatic issues; vaccines, therapeutics, and immunotherapeutics: David Cho
E-mail: choda@niaid.nih.gov
Cooperative research partnerships: Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Adjuvants: Sonnie Kim
E-mail: skim@niaid.nih.gov
Diagnostics: Karen Lacourciere
E-mail: lacourcierek@niaid.nih.gov
Development of Therapeutic Agents for Selected Biodefense Bacterial Diseases *
Objective: To advance the development of candidate therapeutics with (1) demonstrated activity against one or more of the selected NIAID Category A and B biothreat bacterial pathogens or (2) broad spectrum activity against any of the Category C antimicrobial resistant pathogens and one more of the selected Category A and B bacterial pathogens. Product development shall be via a focused, staged approach and include candidate therapeutics within the regulatory purview of the Center for Drug Evaluation and Review (CDER) of the U.S. Food and Drug Administration (FDA).
Contact Info
Carl Newman
E-mail: cnewman@niaid.nih.gov
Development of Therapeutic Agents for Selected Viral Diseases*
Objective: To develop new, safe, and effective therapeutics for Variola major and viral hemorrhagic fevers, viral encephalitides, and influenza.
Contact Info
Liem Nguyen
E-mail: lnguyen@niaid.nih.gov
NIAID Small Business Biodefense Program
Objective: To encourage Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) applications to develop therapeutics, vaccines, adjuvants/immunostimulants, diagnostics, and selected resources for biodefense.
Contact Info
Barbara Mulach
E-mail: bmulach@nih.gov
Partnerships to Improve Diagnosis and Treatment of Selected Drug-Resistant Healthcare-Associated Infections
Objective: To support the development of rapid diagnostics and therapeutics for select drug-resistant healthcare-associated infections
Contact Info
Edward Schroder
Email: eschroder@niaid.nih.gov
Production and Testing of Anthrax Recombinant Protective Antigen (rPA) Vaccine *
Objectives: To continue initial work on a promising vaccine concept, transitioning from pilot scale manufacturing to larger scale production of consistency lots. To continue to take this experimental vaccine strategy through several stages of development, including scaled manufacturing, testing for safety in laboratory and clinical trials, testing for efficacy in animals, and preparing and submitting all necessary Food and Drug Administration (FDA) applications.
Contact Info
Edwin Nuzum
E-mail: enuzum@niaid.nih.gov
Clinical Trial for Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections
Objective: To conduct a multi-site Phase II/III clinical trial to evaluate off-patent antimicrobials and/or wound care for the management of uncomplicated skin and soft tissue infection among outpatients in areas of the US where prevalence of CA-MRSA is high.
Contact Info
Ross Kelley
Email: rkelley@niaid.nih.gov
Cooperative Research into Therapeutics and Diagnostics for Category B Bacteria, Viruses, and Parasites
Objective: To support translational research and pre-clinical product development of new therapeutics and diagnostics addressing NIAID Category B priority pathogens.
Contact Info
General scientific and programmatic issues and questions, Category B bacteria: Robert Hall
E-mail: rhall@niaid.nih.gov
Questions related to Category B viruses: Cristina Cassetti
E-mail: ccassetti@niaid.nih.gov
Questions related to Category B Parasites: Philip Coyne
E-mail: pcoyne@niaid.nih.gov
Cooperative Research Partnerships into Therapeutics and Diagnostics for Biodefense Toxins (U01) (RFA-AI-06-035)
Objective: To support cooperative translational research into developing therapeutics and diagnostics for certain biodefense toxins: Shiga toxins, ricin toxin, the Staphylococcus enterotoxin B (SEB), Clostridium perfringens epsilon toxin, and the botulinum neurotoxins.
Contact Info
General scientific, technical, and programmatic issues: Clare K. Schmitt
E-mail: CSchmitt@niaid.nih.gov
Therapeutics and immunotherapeutics questions: Lillian Van De Verg
E-mail: lvandeverg@niaid.nih.gov
Diagnostics questions: Robert Hall
E-mail: rhall@niaid.nih.gov
NIAID Centers of Excellence for Influenza Research and Surveillance
Objective: To carry out an international and/or domestic animal surveillance program with emphasis on the rapid characterization of influenza viruses with pandemic potential; to carry out a research program to determine the factors that influence influenza viruses, and characterize the immune response to influenza infection and/or vaccination.
Contact Info
Carl Newman
E-mail: cnewman@niaid.nih.gov
NIAID Structural Genomics Centers for Infectious Disease
Objective: To apply state-of-the-art structural genomics technologies to structurally characterize targeted proteins from NIAID Category A-C pathogens and organisms causing emerging or re-emerging infectious diseases.
Contact Info
Robert Singman
E-mail: RSingman@niaid.nih.gov
* Funding for this contract was jointly made through NIAID and the Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA), which systematically coordinates the development and purchase of vaccines, therapies and diagnostic tools for public health medical emergencies.
back to top